Published in Int Urogynecol J on September 07, 2010
Stem cell therapy for stress urinary incontinence: a critical review. Stem Cells Dev (2012) 1.18
Prospects of stem cell treatment in benign urological diseases. Korean J Urol (2015) 0.85
Regenerative medicine based applications to combat stress urinary incontinence. World J Stem Cells (2013) 0.84
Autologous adipose stem cells in treatment of female stress urinary incontinence: results of a pilot study. Stem Cells Transl Med (2014) 0.81
The dose-effect safety profile of skeletal muscle precursor cell therapy in a dog model of intrinsic urinary sphincter deficiency. Stem Cells Transl Med (2015) 0.75
The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology (2003) 9.92
Myoblast transplantation for heart failure. Lancet (2001) 2.71
Urinary incontinence in women. Lancet (2006) 2.22
Systematic review: randomized, controlled trials of nonsurgical treatments for urinary incontinence in women. Ann Intern Med (2008) 2.22
Differential myocardial infarct repair with muscle stem cells compared to myoblasts. Mol Ther (2005) 1.59
1-year follow-up of autologous muscle-derived stem cell injection pilot study to treat stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct (2008) 1.45
Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review. Eur Urol (2006) 1.17
Autologous transplantation of muscle-derived CD133+ stem cells in Duchenne muscle patients. Cell Transplant (2007) 1.16
Preliminary results of myoblast injection into the urethra and bladder wall: a possible method for the treatment of stress urinary incontinence and impaired detrusor contractility. Neurourol Urodyn (2000) 1.07
Clinical practice. Urinary stress incontinence in women. N Engl J Med (2008) 1.02
Female stress urinary incontinence due to intrinsic sphincteric deficiency: recognition and management. J Urol (1996) 0.99
Persistence and survival of autologous muscle derived cells versus bovine collagen as potential treatment of stress urinary incontinence. J Urol (2001) 0.91
Stem cell therapy for urinary stress incontinence. Exp Gerontol (2004) 0.90
Restoration of functional motor units in a rat model of sphincter injury by muscle precursor cell autografts. Transplantation (2003) 0.90
European psychometric validation of the CONTILIFE: a Quality of Life questionnaire for urinary incontinence. Eur Urol (2003) 0.87
Clinical and urodynamic features of intrinsic sphincter deficiency. Neurourol Urodyn (2003) 0.85
Management of intrinsic sphincteric deficiency in women. J Urol (2003) 0.85
Complications of Teflon injection for stress urinary incontinence. Neurourol Urodyn (1993) 0.83
Fate of implanted syngenic muscle precursor cells in striated urethral sphincter of female rats: perspectives for treatment of urinary incontinence. Urology (2004) 0.82
Improvement of urethral sphincter deficiency in female rats following autologous skeletal muscle myoblasts grafting. Cell Transplant (2007) 0.81
Current management of stress urinary incontinence. BJU Int (2004) 0.76
Photoselective vaporization of the prostate with GreenLight 120-W laser compared with monopolar transurethral resection of the prostate: a multicenter randomized controlled trial. Eur Urol (2012) 2.80
Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol (2005) 2.68
Treatment of postprostatectomy male urinary incontinence with the transobturator retroluminal repositioning sling suspension: 3-year follow-up. Eur Urol (2012) 2.43
The artificial urinary sphincter after a quarter of a century: a critical systematic review of its use in male non-neurogenic incontinence. Eur Urol (2012) 2.37
Regional copy number-independent deregulation of transcription in cancer. Nat Genet (2006) 2.33
The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int (2005) 2.31
Mesenchymal stem cell abnormalities in patients with multiple myeloma. Leuk Lymphoma (2007) 1.66
Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol (2013) 1.65
FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res (2003) 1.64
Duloxetine for mild to moderate postprostatectomy incontinence: preliminary results of a randomised, placebo-controlled trial. Eur Urol (2010) 1.56
Design and validation of a new screening instrument for lower urinary tract dysfunction: the bladder control self-assessment questionnaire (B-SAQ). Eur Urol (2006) 1.43
Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot phase II study. World J Urol (2013) 1.42
Prospective, multidimensional evaluation of sexual disorders in men after laser photovaporization of the prostate. J Sex Med (2013) 1.42
Oncologic outcomes and survival in pT0 tumors after radical cystectomy in patients without neoadjuvant chemotherapy: results from a large multicentre collaborative study. Ann Surg Oncol (2011) 1.42
The AdVance transobturator male sling for postprostatectomy incontinence: clinical results of a prospective evaluation after a minimum follow-up of 6 months. Eur Urol (2009) 1.32
Activating mutations of Gsalpha in kidney cancer. J Urol (2006) 1.31
Urinary incontinence in French women: prevalence, risk factors, and impact on quality of life. Eur Urol (2009) 1.30
Renal cell carcinoma of native kidney in renal transplant recipients. BJU Int (2006) 1.26
Late metastasis of renal cell carcinoma to the submaxillary gland 10 years after radical nephrectomy. Int J Urol (2006) 1.19
Objective and subjective cure rates after trans-obturator tape (OBTAPE) treatment of female urinary incontinence. Eur Urol (2005) 1.13
Midterm prospective evaluation of TVT-Secur reveals high failure rate. Eur Urol (2010) 1.13
Mid-term evaluation of the transobturator male sling for post-prostatectomy incontinence: focus on prognostic factors. BJU Int (2010) 1.09
Overactive bladder medical management in the elderly: it is time to go beyond the tip of the iceberg. Eur Urol (2013) 1.08
Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens. Carcinogenesis (2004) 1.07
Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int (2005) 1.06
Results of the tension-free vaginal tape technique in the elderly. Eur Urol (2003) 1.00
Laparoscopic excision of seminal vesicle cyst revealed by obstruction urinary symptoms. Int J Urol (2006) 0.98
Assessment of oncologic control obtained after open versus laparoscopic nephroureterectomy for upper urinary tract urothelial carcinomas (UUT-UCs): results from a large French multicenter collaborative study. Ann Surg Oncol (2011) 0.98
H19 antisense RNA can up-regulate Igf2 transcription by activation of a novel promoter in mouse myoblasts. PLoS One (2012) 0.98
Overactive bladder: Is there a link to the metabolic syndrome in men? Neurourol Urodyn (2010) 0.98
Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. World J Urol (2010) 0.97
Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases. Hum Genet (2015) 0.95
A French multicenter clinical trial of SPARC for stress urinary incontinence. Eur Urol (2003) 0.95
The safety of the inside-out transobturator approach for transvaginal tape (TVT-O) treatment in stress urinary incontinence: French registry data on 984 women. Int Urogynecol J Pelvic Floor Dysfunct (2008) 0.94
An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries. Eur Urol (2005) 0.94
Multiple phosphorylation events control mitotic degradation of the muscle transcription factor Myf5. BMC Biochem (2005) 0.91
Management of lower urinary tract symptoms related to benign prostatic hyperplasia in real-life practice in france: a comprehensive population study. Eur Urol (2013) 0.86
Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct (2006) 0.86
Occupational exposure to polycyclic aromatic hydrocarbons influenced neither the frequency nor the spectrum of FGFR3 mutations in bladder urothelial carcinoma. Mol Carcinog (2010) 0.86
Complications of urethral sling procedures. Curr Opin Obstet Gynecol (2002) 0.85
Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG). Eur Urol (2004) 0.85
A critical review of diagnostic criteria for evaluating patients with symptomatic stress urinary incontinence. BJU Int (2005) 0.84
Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration. Eur Urol (2003) 0.84
Sensitive allele-specific PCR assay able to detect FGFR3 mutations in tumors and urine from patients with urothelial cell carcinoma of the bladder. Clin Chem (2005) 0.83
The oncologic impact of a delay between diagnosis and radical nephroureterectomy due to diagnostic ureteroscopy in upper urinary tract urothelial carcinomas: results from a large collaborative database. World J Urol (2012) 0.83
Nephron-sparing surgery for de novo renal cell carcinoma in allograft kidneys. Transplantation (2005) 0.83
Assessment of treatment-seeking behavior and healthcare utilization in an international cohort of subjects with overactive bladder. Curr Med Res Opin (2014) 0.83
[Recommendations to general practice doctors for first line management of erectile dysfunction]. Prog Urol (2005) 0.83
Fate of implanted syngenic muscle precursor cells in striated urethral sphincter of female rats: perspectives for treatment of urinary incontinence. Urology (2004) 0.82
Bilateral anterior sacrospinous ligament suspension associated with a paravaginal repair with mesh: short-term clinical results of a pilot study. Int Urogynecol J (2010) 0.82
Pelvic organ prolapse transvaginal repair by the Prolift system: evaluation of efficacy and complications after a 4.5 years follow up. Int J Urol (2012) 0.82
[French multicentre prospective study of the use of ACT balloons (Uromedica, Inc., Plymouth, Min, U.S.A.; Medtronic, Minneapolis, U.S.A.) for the treatment of female stress urinary incontinence]. Prog Urol (2007) 0.81
First clinical evaluation of a new innovative ureteral access sheath (Re-Trace™): a European study. World J Urol (2013) 0.80
Ajust single incision transobturator sling procedure for stress urinary incontinence: results after 1-year follow-up. Int Urogynecol J (2012) 0.80
Evolution of the landscape of surgical management of prostate cancer in France: the case of radical prostatectomy. Eur Urol (2012) 0.80
[Medium-term results of grade 3 and 4 cystocele repair by porcine xenograft matrix (pelvicol)]. Prog Urol (2007) 0.80
Serum sex steroids measured in middle-aged European and African-Caribbean men by gas chromatography-mass spectrometry. Eur J Endocrinol (2011) 0.80
Nocturnal polyuria: it's all about definition, and be Patient! Eur Urol (2012) 0.79
Dose effect relationship between the number of normal progenitor muscle cells grafted in mdx mouse skeletal striated muscle and the number of dystrophin-positive fibres. Neurosci Lett (2003) 0.79
Early experience with sildenafil for the treatment of erectile dysfunction in renal transplant recipients. Nephrol Dial Transplant (2003) 0.79
A new platelet cryoprecipitate glue promoting bone formation after ectopic mesenchymal stromal cell-loaded biomaterial implantation in nude mice. Stem Cell Res Ther (2013) 0.79
Anterior sacrospinous ligament fixation associated with paravaginal repair using the Pinnacle device: an anatomical study. Int Urogynecol J (2011) 0.79
Impact of laparoscopic sacrocolpopexy on symptoms, health-related quality of life and sexuality: a medium-term analysis. BJU Int (2013) 0.78
Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence. Clin Interv Aging (2009) 0.78
TVT SECUR single-incision sling after 5 years of follow-up: the promises made and the promises broken. Eur Urol (2012) 0.78
[Management of urinary tract infections in women. Epidemiologic survey of 7916 women in general practice]. Presse Med (2006) 0.78
Transobturator male sling TOMS for the treatment of stress post-prostatectomy incontinence, initial experience and results with one year's experience. Int Braz J Urol (2009) 0.78
[Non-typhus Salmonella urinary tract infections]. Prog Urol (2002) 0.78
Pygeum africanum extract inhibits proliferation of human cultured prostatic fibroblasts and myofibroblasts. BJU Int (2006) 0.78
Restoration of anal sphincter function after myoblast cell therapy in incontinent rats. Cell Transplant (2013) 0.78
Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med (2012) 0.77
Antegrade percutaneous flexible endoscopic approach for the management of urinary diversion-associated complications. J Endourol (2013) 0.77
Use of a serum-free medium to produce in vitro Neospora caninum and Toxoplasma gondii tachyzoites on Vero cells. Vet Res (2002) 0.77
[Solitary fibrous tumours of the kidney]. Prog Urol (2004) 0.76
LUTS (R)evolution: let's jump on the bandwagon. Eur Urol (2013) 0.76
Prospective evaluation of genetic abnormalities and telomerase expression in exfoliated urinary cells for bladder cancer detection. J Urol (2002) 0.76
Biological effect of human serum collected before and after oral intake of Pygeum africanum on various benign prostate cell cultures. Asian J Androl (2011) 0.76
Gene therapy for rheumatoid arthritis. J Gene Med (2002) 0.76
Prevention of prostate cancer by androgens: experimental paradox or clinical reality. Eur Urol (2004) 0.76
Bladder function after radical hysterectomy for cervical cancer. Neurourol Urodyn (2014) 0.76
Evidence of occult dysautonomia in Fowler's syndrome: alteration of cardiovascular autonomic function tests in female patients presenting with urinary retention. BJU Int (2006) 0.75
Mirabegron as a new class of oral drug for overactive bladder syndrome: many positive perspectives, some concerns. Eur Urol (2012) 0.75
Comparative effectiveness research in urology: a step toward better therapeutic decision making. Eur Urol (2012) 0.75
Gefitinib inhibits the growth and invasion of urothelial carcinoma cell lines in which Akt and MAPK activation is dependent on constitutive epidermal growth factor receptor activation. Clin Cancer Res (2006) 0.75
Mini-slings for female stress urinary incontinence: not yet at the age of reason. Eur Urol (2011) 0.75